Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Other Non Operating Income: 2020-2024

Historic Other Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $2.5 million.

  • SAB Biotherapeutics' Other Non Operating Income rose 1.49% to $765,881 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 27.26%. This contributed to the annual value of $2.5 million for FY2024, which is 463.70% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Other Non Operating Income stood at $2.5 million for FY2024, which was up 463.70% from $435,089 recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Other Non Operating Income registered a high of $2.5 million during FY2024, and its lowest value of $3,996 during FY2020.
  • Moreover, its 3-year median value for Other Non Operating Income was $435,089 (2023), whereas its average is $973,816.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 16,556.56% in 2021, then crashed by 94.93% in 2022.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Other Non Operating Income stood at $3,996 in 2020, then skyrocketed by 16,556.56% to $665,596 in 2021, then tumbled by 94.93% to $33,754 in 2022, then skyrocketed by 1,189.00% to $435,089 in 2023, then soared by 463.70% to $2.5 million in 2024.